Literature DB >> 33530109

Favorable effect of endoscopic reassessment of clinically staged T2 esophageal adenocarcinoma: a multicenter prospective cohort study.

Steffi E M van de Ven1, Manon C W Spaander1, Roos E Pouw2, Thjon J Tang3, Martin H M G Houben4, Erik J Schoon5, Pieter J F de Jonge1, Marco J Bruno1, Arjun D Koch1.   

Abstract

BACKGROUND : Clinical tumor stage of esophageal adenocarcinoma (EAC) is determined by endoscopic ultrasound and/or computed tomography scan, which have low accuracy for stages T1 and T2, potentially leading to overtreatment. We aimed to assess the proportion of cT2 EACs downstaged to cT1 after endoscopic reassessment (ERA) by an experienced interventional endoscopist. METHODS : We performed a prospective multicenter cohort study. Patients with cT2N0M0 EAC were included and underwent ERA. The primary outcome was proportion of cT2 EACs downstaged to cT1 after ERA. RESULTS : 15/25 included patients (60 %) were downstaged from cT2 to cT1 EAC after ERA and underwent attempted endoscopic resection. Endoscopic resection was aborted in 3/15 patients because of tumor invasion into the muscle layer; all three underwent successful surgical resection. Endoscopic resection was successful in 12/15 patients (80 %), all of whom had pT1 tumors. Overall, 10/25 (40 %) were treated with endoscopic resection alone. CONCLUSIONS : ERA downstaged about half of the cT2 tumors to cT1, rendering them suitable for endoscopic resection. ERA had substantial clinical impact on therapeutic management, preventing overtreatment in 40 % of patients. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33530109     DOI: 10.1055/a-1380-8899

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   9.776


  1 in total

1.  Impact of endoscopic ultrasonography on the accuracy of T staging in esophageal cancer and factors associated with its accuracy: A retrospective study.

Authors:  Mingbo Wang; Yonggang Zhu; Zhenhua Li; Peng Su; Wenda Gao; Chao Huang; Ziqiang Tian
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.